Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety trial of nivolumab in previously treated metastatic renal cell carcinoma
2015-004117-24Phase 2Completed
- Sponsor
- Unicancer
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by Unicancer. Primary endpoint: Incidence of high-grade adverse reactions of interest. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2015-004117-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004117-24.